Allergan, Takeda & more — 7 GI company key notes

Here are seven updates on GI companies from the past week:

gMed, a Modernizing Medicine Co., completed its rebrand to become Modernizing Medicine Gastroenterology.

A series of studies confirmed Synergy Pharmaceuticals' Trulance was effective in older patients with chronic idiopathic constipation or irritable bowel syndrome with constipation.

Allergan launched two global clinical research programs for its inflammatory bowel disease drug, brazikumab.

CSA Medical received $23 million in venture debt and equity financing to advance its pair of cryospray therapies.

A single dose of Janssen Pharmaceuticals' Stelara induced clinical remission in patients with moderate to severe ulcerative colitis,

Takeda is presenting long-term efficacy and real-world data for Entyvio at ACG 2018 in Philadelphia Oct. 5-10.

CDx Diagnostics presented Wide Area Transepithelial Sampling with 3D Tissue Analysis data showing crypt dysplasia played a role in high-grade esophageal dysplasia and esophageal cancer at ACG 18, Oct. 5-10 in Philadelphia.

More articles on gastroenterology:
Takeda presents 3 studies examining Entyvio's long-term efficacy
Janssen Pharmaceuticals' ulcerative colitis drug induces clinical remission — 5 insights
WATS3D confirms crypt dysplasia as a cancer risk factor in Barrett's esophagus patients — 5 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months